VITA 34 AI Stock Analysis
Want to see DE:V3V full AI Analyst Report?
VITA 34 (V3V) AI Stock Analysis
VITA 34
(XETRA:V3V)
Vita 34 scores poorly overall, driven primarily by a structurally fragile financial profile: despite strong revenue growth and a genuine recovery in margins and cash flow, the company is still loss-making and shareholders' equity has eroded to just €5.1M against €162M of assets, lifting debt-to-equity to 4.6x. Technicals reinforce the caution, with the price well below all major moving averages and negative MACD momentum, though oversold RSI and Stochastic readings hint at scope for a short-term rebound. Valuation provides no support, as the negative P/E reflects losses and there is no dividend. The investment case rests entirely on whether the recent cash flow and margin improvements can be sustained long enough to repair the balance sheet.
VITA 34 (V3V) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 40.09M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,422
- Price to Earnings (P/E)
- -5.3
- Beta (1Y)
- 0.12
- Revenue Growth
- 0.06%
- EPS Growth
- 22.84%
- Country
- Germany
- Employees
- 723
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
VITA 34 Business Overview & Revenue Model
Company Description
FamiCord AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced therap...
VITA 34 Financial Statement Overview
Summary
Revenue has more than tripled since 2021 and grew 23.1% in the latest TTM period, while gross margin recovered to 61.7% and EBITDA turned positive at €5.6M. Cash flow is the relative bright spot, with €7.1M operating cash flow and €4.3M free cash flow. However, the company remains loss-making at both the operating (-€2.7M) and net (-€7.7M) level, with the net loss widening. The balance sheet is the key risk: equity has collapsed from €43.1M in 2021 to just €5.1M against €162M of assets and €23M of debt, pushing leverage to 4.6x and leaving virtually no cushion against further setbacks.
Income Statement
34NegativeBalance Sheet
20Very NegativeCash Flow
51Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 87.78M | 88.17M | 82.18M | 77.06M | 68.94M | 28.42M |
| Gross Profit | 54.13M | 44.84M | 20.65M | 28.24M | 2.73M | 12.44M |
| EBITDA | 5.65M | 4.76M | -443.00K | 5.81M | -18.34M | 791.00K |
| Net Income | -7.67M | -6.30M | -12.14M | -1.86M | -27.39M | -3.93M |
Balance Sheet | ||||||
| Total Assets | 162.35M | 168.26M | 152.74M | 158.36M | 151.51M | 177.95M |
| Cash, Cash Equivalents and Short-Term Investments | 12.45M | 11.88M | 18.46M | 17.42M | 18.23M | 35.26M |
| Total Debt | 23.03M | 23.51M | 18.10M | 21.57M | 28.18M | 32.32M |
| Total Liabilities | 158.45M | 162.84M | 139.83M | 135.58M | 135.66M | 136.00M |
| Stockholders Equity | 5.05M | 7.12M | 14.13M | 23.56M | 16.50M | 43.07M |
Cash Flow | ||||||
| Free Cash Flow | 4.32M | -249.00K | 5.46M | 5.06M | -10.92M | 467.00K |
| Operating Cash Flow | 7.14M | 3.88M | 8.65M | 9.15M | -4.49M | 2.73M |
| Investing Cash Flow | -7.82M | -12.66M | -3.08M | -3.57M | -5.81M | 24.87M |
| Financing Cash Flow | 1.61M | 3.89M | -6.09M | -5.09M | -6.27M | -4.70M |
VITA 34 Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:V3V, the sentiment is Negative. The current price of 2.30 is below the 20-day moving average (MA) of 2.57, below the 50-day MA of 2.80, and below the 200-day MA of 3.66, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 27.27 is Positive, neither overbought nor oversold. The STOCH value of 21.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:V3V.
VITA 34 Peers Comparison
Overall Rating
DE:MED62Neutral
DE:ILM159Neutral
DE:SBS54Neutral
DE:V3V39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 62Neutral | EUR 249.38M | 7.98 | 11.94% | 0.76% | 0.77% | -11.41% | |
| 59Neutral | EUR 269.85M | 24.05 | 2.16% | ― | 8.41% | -61.58% | |
| 54Neutral | EUR 347.66M | -8.19 | -18.69% | 2.10% | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 39Underperform | EUR 40.09M | -5.30 | -94.93% | ― | 0.06% | 22.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:V3V | VITA 34 | 2.30 | -3.00 | -56.60% | |
| DE:MED | MEDICLIN AG | 5.25 | 1.89 | 56.06% | |
| DE:SBS | STRATEC Biomedical | 28.60 | 9.08 | 46.48% | |
| DE:ILM1 | Medios AG | 10.58 | -3.20 | -23.22% | |
| DE:HAEK | HAEMATO AG | 13.30 | 4.73 | 55.14% | |
| DE:7V0 | Novogenia Holding AG | 5.30 | -1.69 | -24.13% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
